THE STAMFORD HOSPITAL
- Type
- Teaching hospital
- Where
- Stamford, CT
- Medicare CCN
- 070006
- Received
- $253,938 in 108 records, 2019 ($29,705 general, $224,232 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: STAMFORD HOSPITAL Fuzzy (name and state)
- Plan sponsor: STAMFORD HOSPITAL Fuzzy (name and state)
- Federal award recipient: STAMFORD HOSPITAL Fuzzy (name and state)
- Federal award recipient: STAMFORD HOSPITAL Fuzzy (name and state)
- Lobbying client: STAMFORD HOSPITAL Fuzzy (name and state)
- Lobbying client: STAMFORD HOSPITAL Fuzzy (name and state)
- Nonprofit: STAMFORD HOSPITAL Fuzzy (name and state)
- Trademark owner: The Stamford Hospital Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2019 | General payment | 29 | $29,705 |
| 2019 | Research payment | 79 | $224,232 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| HOLOGIC INC | 7 | $38,945 | 2019 |
| Halozyme Inc | 3 | $36,200 | 2019 |
| Celgene Corporation | 5 | $29,742 | 2019 |
| F. Hoffmann-La Roche AG | 2 | $23,829 | 2019 |
| AKEBIA THERAPEUTICS INC | 28 | $20,487 | 2019 |
| Bayer Healthcare Pharmaceuticals Inc. | 8 | $14,163 | 2019 |
| Genentech, Inc. | 5 | $14,016 | 2019 |
| Janssen Research & Development, LLC | 1 | $11,400 | 2019 |
| Amgen Inc. | 3 | $10,772 | 2019 |
| CSL Behring | 3 | $9,586 | 2019 |
| Medtronic MiniMed, Inc. | 3 | $8,575 | 2019 |
| E.R. Squibb & Sons, L.L.C. | 4 | $7,382 | 2019 |
| Stryker Corporation | 17 | $6,709 | 2019 |
| Incyte Corporation | 3 | $5,966 | 2019 |
| Zimmer Biomet Holdings, Inc. | 1 | $4,680 | 2019 |
| Abbott Laboratories | 4 | $3,016 | 2019 |
| American Regent | 1 | $2,800 | 2019 |
| ABBVIE INC. | 1 | $1,000 | 2019 |
| Gilead Sciences, Inc. | 1 | $1,000 | 2019 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $1,000 | 2019 |
| Allergan, Inc. | 1 | $1,000 | 2019 |
| Boston Scientific Corporation | 3 | $924 | 2019 |
| Tandem Diabetes Care, Inc. | 2 | $600 | 2019 |
| Welch Allyn | 1 | $141 | 2019 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 79 | $224,232 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 21 | $11,771 |
| Gift | 3 | $8,934 |
| Grant | 1 | $5,000 |
| Space rental or facility fees (teaching hospital only) | 3 | $3,000 |
| Education | 1 | $1,000 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2019-12-31 | Zimmer Biomet Holdings, Inc. | $4,680 | Gift | In-kind items and services | Zimmer Biomet Instruments and Implants Device, General | 2019 | |
| 2019-12-31 | Stryker Corporation | $4,113 | Gift | In-kind items and services | HIP ARTHROSCOPY ACCESS & INSTRUMENTATION SET Device, ARTHROSCOPY | 2019 | |
| 2019-12-20 | Medtronic MiniMed, Inc. | $3,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Minimed 670G System Device, Durable Pump | 2019 | |
| 2019-12-19 | Janssen Research & Development, LLC | $11,400 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects with High-risk, Localized or Lo | 2019 | |
| 2019-12-13 | Bayer Healthcare Pharmaceuticals Inc. | $1,834 | Research payment | Cash or cash equivalent | Non-Covered | BAY1002670 Long term Safety vs SoC | 2019 |
| 2019-12-10 | AKEBIA THERAPEUTICS INC | $215 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-12-10 | AKEBIA THERAPEUTICS INC | $215 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-12-10 | AKEBIA THERAPEUTICS INC | $152 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-12-10 | Welch Allyn | $141 | Gift | Cash or cash equivalent | 2019 | ||
| 2019-12-10 | AKEBIA THERAPEUTICS INC | $126 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-12-06 | Genentech, Inc. | $1,587 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | A PHASE III OF ATEZOLIZUMAB PLUS ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER | 2019 |
| 2019-12-03 | AKEBIA THERAPEUTICS INC | $976 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-12-03 | AKEBIA THERAPEUTICS INC | $493 | Research payment | Cash or cash equivalent | AKB-6548-CI-0014 | 2019 | |
| 2019-12-02 | Boston Scientific Corporation | $224 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | APPRAISE ATP | 2019 |
| 2019-11-25 | HOLOGIC INC | $5,000 | Research payment | Cash or cash equivalent | 16-04 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $952 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $887 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $825 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $825 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $825 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $825 | Research payment | Cash or cash equivalent | AKB-6548-CI-0014 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $825 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $825 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $825 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $825 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $825 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $825 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $825 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-04 | Genentech, Inc. | $293 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PHASE 3 STUDY OF ANTI PDL1 WITH ABRAXANE IN TN MBC | 2019 |
| 2019-10-30 | Celgene Corporation | $2,500 | Research payment | Cash or cash equivalent | Revlimid Drug, Hematology / Oncology | Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Regist | 2019 |
| 2019-10-30 | Abbott Laboratories | $292 | Research payment | Cash or cash equivalent | CardioMEMS Device, Cardiac Arrhythmias and Heart Failure | CardioMEMS HF System Post Approval Study | 2019 |
| 2019-10-29 | F. Hoffmann-La Roche AG | $7,880 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | ALL COMERS SSF | 2019 |
| 2019-10-24 | CSL Behring | $6,461 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-10-24 | CSL Behring | $2,850 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-10-24 | CSL Behring | $275 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-10-15 | Celgene Corporation | $4,125 | Research payment | Cash or cash equivalent | Revlimid Drug, Hematology / Oncology | Connect MM- The Multiple Myeloma Disease Registry (OS002982) | 2019 |
| 2019-10-09 | Stryker Corporation | $449 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-10-09 | Stryker Corporation | $219 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-10-09 | Stryker Corporation | $27 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-10-09 | Stryker Corporation | $23 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-10-04 | Genentech, Inc. | $921 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PHASE 3 STUDY OF ANTI PDL1 WITH ABRAXANE IN TN MBC | 2019 |
| 2019-10-02 | AKEBIA THERAPEUTICS INC | $854 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-09-16 | Boston Scientific Corporation | $350 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | APPRAISE ATP | 2019 |
| 2019-09-05 | HOLOGIC INC | $2,799 | Research payment | Cash or cash equivalent | Oryx 2 Device, Breast and Skeletal Health | 17-09 | 2019 |
| 2019-08-29 | Medtronic MiniMed, Inc. | $3,525 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Minimed 670G System Device, Durable Pump | 2019 | |
| 2019-08-08 | Bayer Healthcare Pharmaceuticals Inc. | $2,155 | Research payment | Cash or cash equivalent | Non-Covered | BAY1002670 Long term Safety vs SoC | 2019 |
| 2019-08-07 | Amgen Inc. | $1,807 | Research payment | In-kind items and services | Neulasta Biological, Oncology | Prospective Observational Study of Onpro vs SOC | 2019 |
| 2019-08-07 | Gilead Sciences, Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-08-06 | F. Hoffmann-La Roche AG | $15,949 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | ALL COMERS SSF | 2019 |
| 2019-08-06 | Halozyme Inc | $6,473 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase | 2019 | |
| 2019-07-24 | Abbott Laboratories | $520 | Research payment | Cash or cash equivalent | CardioMEMS Device, Cardiac Arrhythmias and Heart Failure | CardioMEMS HF System Post Approval Study | 2019 |
| 2019-07-18 | HOLOGIC INC | $4,286 | Research payment | Cash or cash equivalent | Trident HD Device, Breast and Skeletal Health | 17-05 | 2019 |
| 2019-07-16 | Stryker Corporation | $329 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-07-16 | Stryker Corporation | $159 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-07-16 | Stryker Corporation | $38 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-07-16 | Stryker Corporation | $21 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-07-08 | AKEBIA THERAPEUTICS INC | $825 | Research payment | Cash or cash equivalent | AKB-6548-CI-0014 | 2019 | |
| 2019-06-24 | Medtronic MiniMed, Inc. | $1,800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Minimed 670G System Device, Durable Pump | 2019 | |
| 2019-06-21 | E.R. Squibb & Sons, L.L.C. | $5,000 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-06-13 | AKEBIA THERAPEUTICS INC | $825 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-05-30 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-05-28 | Bayer Healthcare Pharmaceuticals Inc. | $476 | Research payment | Cash or cash equivalent | Non-Covered | BAY1002670 Long term Safety vs SoC | 2019 |
| 2019-05-25 | Amgen Inc. | $8,070 | Research payment | Cash or cash equivalent | Neulasta Biological, Oncology | Prospective Observational Study of Onpro vs SOC | 2019 |
| 2019-05-24 | HOLOGIC INC | $5,000 | Research payment | Cash or cash equivalent | 16-04 | 2019 | |
| 2019-05-23 | Incyte Corporation | $1,504 | Research payment | Cash or cash equivalent | PROSPECTIVE, NON INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED | 2019 | |
| 2019-05-22 | Celgene Corporation | $17,250 | Research payment | Cash or cash equivalent | Revlimid Drug, Hematology / Oncology | Celgene - Connect MM | 2019 |
| 2019-05-16 | E.R. Squibb & Sons, L.L.C. | $90 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | A Master Protocol of Phase II Studies of Nivolumab in Advanced NSCLC Nivolumab as Maintenance after Induction Chemothera | 2019 |
| 2019-05-07 | Bayer Healthcare Pharmaceuticals Inc. | $3,736 | Research payment | Cash or cash equivalent | Non-Covered | BAY1002670 Long term Safety vs SoC | 2019 |
| 2019-05-07 | Bayer Healthcare Pharmaceuticals Inc. | $2,586 | Research payment | Cash or cash equivalent | Non-Covered | BAY1002670 Long term Safety vs SoC | 2019 |
| 2019-05-07 | Bayer Healthcare Pharmaceuticals Inc. | $1,293 | Research payment | Cash or cash equivalent | Non-Covered | BAY1002670 Long term Safety vs SoC | 2019 |
| 2019-05-07 | Bayer Healthcare Pharmaceuticals Inc. | $1,293 | Research payment | Cash or cash equivalent | Non-Covered | BAY1002670 Long term Safety vs SoC | 2019 |
| 2019-05-07 | ABBVIE INC. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Creon Drug, Endocrinology | 2019 | |
| 2019-05-07 | Bayer Healthcare Pharmaceuticals Inc. | $790 | Research payment | Cash or cash equivalent | Non-Covered | BAY1002670 Long term Safety vs SoC | 2019 |
| 2019-05-06 | AKEBIA THERAPEUTICS INC | $887 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-05-06 | AKEBIA THERAPEUTICS INC | $887 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-05-06 | AKEBIA THERAPEUTICS INC | $825 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-05-06 | AKEBIA THERAPEUTICS INC | $825 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-05-06 | AKEBIA THERAPEUTICS INC | $734 | Research payment | Cash or cash equivalent | AKB-6548-CI-0014 | 2019 | |
| 2019-05-06 | AKEBIA THERAPEUTICS INC | $734 | Research payment | Cash or cash equivalent | AKB-6548-CI-0014 | 2019 | |
| 2019-04-29 | Incyte Corporation | $13 | Research payment | Cash or cash equivalent | PROSPECTIVE, NON INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED | 2019 | |
| 2019-04-15 | HOLOGIC INC | $3,760 | Research payment | Cash or cash equivalent | Oryx 2 Device, Breast and Skeletal Health | 17-09 | 2019 |
| 2019-04-12 | Stryker Corporation | $514 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-04-12 | Stryker Corporation | $174 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-04-12 | Stryker Corporation | $27 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-04-12 | Stryker Corporation | $24 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-04-10 | E.R. Squibb & Sons, L.L.C. | $2,112 | Research payment | Cash or cash equivalent | SPRYCEL Drug, Oncology | Studying Interventions for Managing Patients With Chronic Myeloid Leukemia CML in Chronic Phase The 5-Year Prospective C | 2019 |
| 2019-04-10 | Abbott Laboratories | $1,711 | Research payment | Cash or cash equivalent | CardioMEMS Device, Cardiac Arrhythmias and Heart Failure | CardioMEMS HF System Post Approval Study | 2019 |
| 2019-04-10 | VERTEX PHARMACEUTICALS INCORPORATED | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | SYMDEKO Drug, CYSTIC FIBROSIS | 2019 | |
| 2019-04-08 | HOLOGIC INC | $10,000 | Research payment | Cash or cash equivalent | 16-04 | 2019 | |
| 2019-03-21 | Halozyme Inc | $16,538 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase | 2019 | |
| 2019-03-20 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-03-18 | Boston Scientific Corporation | $350 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | APPRAISE ATP | 2019 |
| 2019-03-08 | Genentech, Inc. | $1,843 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PHASE 3 STUDY OF ANTI PDL1 WITH ABRAXANE IN TN MBC | 2019 |
| 2019-03-07 | Halozyme Inc | $13,189 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase | 2019 | |
| 2019-03-04 | Allergan, Inc. | $1,000 | Education | Cash or cash equivalent | 2019 | ||
| 2019-02-20 | Genentech, Inc. | $9,371 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PHASE 3 STUDY OF ANTI PDL1 WITH ABRAXANE IN TN MBC | 2019 |
| 2019-02-19 | E.R. Squibb & Sons, L.L.C. | $180 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | A Master Protocol of Phase II Studies of Nivolumab in Advanced NSCLC Nivolumab as Maintenance after Induction Chemothera | 2019 |
| 2019-02-13 | American Regent | $2,800 | Research payment | Cash or cash equivalent | INJECTAFER Drug, Anemia | Heart_FID | 2019 |
| 2019-02-05 | Incyte Corporation | $4,449 | Research payment | Cash or cash equivalent | PROSPECTIVE, NON INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED | 2019 | |
| 2019-01-22 | Celgene Corporation | $1,367 | Research payment | Cash or cash equivalent | Pomalyst Drug, Hematology / Oncology | Immune profiling of relapsed or refractory multiple myeloma patients treated with pomalidomide and low-dose dexamethason | 2019 |
| 2019-01-18 | Celgene Corporation | $4,500 | Research payment | Cash or cash equivalent | Revlimid Drug, Hematology / Oncology | Celgene - Connect MDSAML | 2019 |
| 2019-01-16 | Abbott Laboratories | $492 | Research payment | Cash or cash equivalent | CardioMEMS Device, Cardiac Arrhythmias and Heart Failure | CardioMEMS HF System Post Approval Study | 2019 |
| 2019-01-08 | Amgen Inc. | $895 | Research payment | In-kind items and services | Neulasta Biological, Oncology | Prospective Observational Study of Onpro vs SOC | 2019 |
| 2019-01-08 | Stryker Corporation | $419 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-01-08 | Stryker Corporation | $117 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-01-08 | Stryker Corporation | $27 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-01-08 | Stryker Corporation | $20 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-01-02 | HOLOGIC INC | $8,100 | Research payment | Cash or cash equivalent | Oryx 2 Device, Breast and Skeletal Health | 17-09 | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Stamford, CT, county Western Connecticut Planning Region, CT, state Connecticut; placed by its city name.
| Measure | Place (city or town) Stamford, CT | County Western Connecticut Planning Region, CT | State Connecticut |
|---|---|---|---|
| Population B01003 | 137,144 | 627,071 | 3,624,508 |
| Population, 2020 census P1 | 135,470 | - | 3,605,944 |
| Median age B01002 | 38.4 | 41.5 | 41.1 |
| Under 18 B01001 | 18.4% | 21.8% | 20.2% |
| 65 and over B01001 | 16.2% | 17.4% | 18.5% |
| Households B11001 | 55,291 | 235,379 | 1,434,007 |
| Foreign born B05002 | 31.3% | 23.8% | 15.7% |
| Median household income B19013 | $111,586 | $128,188 | $95,781 |
| Median family income B19113 | $126,493 | $161,625 | $122,706 |
| Per capita income B19301 | $67,068 | $82,266 | $55,915 |
| Poverty rate B17001 | 10.1% | 7.5% | 10.0% |
| Unemployment rate B23025 | 4.9% | 5.3% | 5.6% |
| Civilian labor force B23025 | 81,944 | 346,557 | 1,959,490 |
| Mean commute (minutes) B08013 | 28.5 | 30.8 | 26.5 |
| Bachelor's degree or higher B15003 | 51.7% | 55.5% | 42.5% |
| Housing units B25001 | 58,655 | 251,530 | 1,541,822 |
| Owner-occupied B25003 | 48.8% | 66.4% | 66.5% |
| Renters B25003 | 51.2% | 33.6% | 33.5% |
| Median home value B25077 | $624,400 | $652,900 | $366,900 |
| Median gross rent B25064 | $2,276 | $2,110 | $1,488 |
| White, not Hispanic B03002 | 43.2% | 58.6% | 61.9% |
| Black B03002 | 17.7% | 9.3% | 9.8% |
| Hispanic or Latino B03002 | 28.3% | 20.5% | 18.3% |
| Asian B03002 | 7.3% | 5.4% | 4.7% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Economy now FRED unemployment 5.1% in Sep 2026 (4.2% a year earlier); per capita personal income $102,307 in 2025, up 33% in five years (+7.1% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Stamford, CT.
Comments